Pathological neovascularization is intimately associated with the progression of several retinal diseases, including retinopathy of prematurity, diabetic retinopathy, and exudative age-related macular degeneration. Neovascularization occurs in response to hypoxia, tissue ischemia, and the consequent production of angiogenic agonists, such as vascular endothelial growth factor A (VEGFA), a potent inducer of vessel formation and vascular leakage (Campochiaro, 2015; Semenza, 2012). The new vessels formed during retinal ischemia are often dysfunctional and fail to stabilize (Fruttiger, 2007; Krock et al., 2011), leading to vessel leakage or hemorrhaging and to retinal detachment, visual impairment, and even blindness. Therefore, suppression of neoangiogenesis, and thereby, retinal edema, is a therapeutic goal in the treatment of ischemic eye diseases (Daruich et al., 2018).

A number of therapeutic options designed to neutralize VEGFA by preventing binding to its receptor, VEGF receptor 2 (VEGFR2), such as bevacizumab, ranibizumab, and aflibercept, decrease neovascular formation as well as edema (Mintz-Hittner et al., 2011). However, they do not correct the underlying hypoxia; in fact, vessel regression may instead further aggravate hypoxia. Moreover, in many cases, anti-VEGF therapies can induce an elevation in intraocular pressure and hemorrhaging (Diabetic Retinopathy Clinical Research Network et al., 2015). The repeated intravitreal injections of anti-VEGF-therapy present a potential for infections and scarring (Patel et al., 2013); in addition, side effects including disrupted neural development in infants have been reported (Canadian Neonatal Network and the Canadian Neonatal Follow-Up Network Investigators et al., 2016). Thus, even though the current therapy improves vision for many patients in the early phases of disease, there is a clear need for developing new treatments to suppress proangiogenic stimuli while also achieving a long-lasting effect with safe administration.

Angiogenesis and vascular permeability in the retina are initiated by the VEGFA/VEGFR2 signaling pathway. VEGFR2 is found not only on blood vascular endothelial cells but also on neuronal cells in the retina, likely contributing to the side effect of VEGFA/VEGFR2 suppression on neural development in premature infants (Nishijima et al., 2007). VEGFR2 activity is initiated through VEGFA-induced receptor dimerization, kinase activation, phosphorylation of tyrosine residues in the receptor intracellular domain, and activation of signaling pathways. The VEGFR2 phosphotyrosine-initiated signaling pathways are now being unraveled. Phosphorylation of Y1212 in VEGFR2 is required for activation of phosphatidyl inositol three kinase and AKT (Testini et al., 2019), while phosphorylation of Y949 is required for activation of the c-Src pathway and regulation of vascular permeability through vascular endothelial (VE)-cadherin (Li et al., 2016). VE-cadherin is the main component of endothelial adherens junctions, strongly implicated in regulation of vascular permeability, leakage, and associated edema (Giannotta et al., 2013). In particular, phosphorylation of the Y685 residue in VE-cadherin correlates with VEGFA-induced vascular hyperpermeability (Smith et al., 2020; Wessel et al., 2014).

Endothelial nitric oxide synthase (eNOS), activated downstream of VEGFA through phosphorylation on S1177 (S1176 in mice) by AKT (Fulton et al., 1999), produces nitric oxide (NO) and regulates vascular permeability. Both mice with a constitutive eNOS gene (Nos3) inactivation (Fukumura et al., 2001) and mice expressing an eNOS serine to alanine point mutation (S1176A) (Nos3^{S1176A/S1176A}) (Di Lorenzo et al., 2013) show reduced extravasation of bovine serum albumin in the healthy skin in response to VEGFA challenge. An important mediator of the effect of eNOS-generated NO is the relaxation of peri-vascular smooth muscle cells (vSMCs), leading to increased vessel diameter and enhanced blood flow and thereby flow-driven vascular sieving (Sessa, 2004). In addition, eNOS activity correlates with tyrosine phosphorylation of VE-cadherin in cultured endothelial cells (Di Lorenzo et al., 2013), providing a mechanism for how eNOS activity may directly affect vascular permeability, distinct from vasodilation.

In contrast to the skin vasculature, the healthy retinal vasculature is protected by a stringent blood-retinal barrier. In retinal diseases, the barrier is disrupted, leading to increased vascular permeability (Zhao et al., 2015). In accordance, NO and related reactive oxygen species (ROS) are important pathogenic agents in retinopathy (Opatrilova et al., 2018). However, the molecular mechanisms whereby eNOS/NO interferes with the retinal vascular barrier and contributes to pathological vascular permeability in eye disease have remained unexplored.

Here, we show that suppressed NO formation via the use of the competitive NOS inhibitor, Nω-Methyl-l-arginine (L-NMMA), which inhibits NO formation from all three NOS variants (eNOS, inducible NOS, and neuronal NOS), or an eNOS mutant, S1176A, negates neovascular tuft formation and vascular leakage during retinal disease. Mechanistically, NO promotes c-Src Y418 phosphorylation at endothelial junctions and phosphorylation of VE-cadherin at Y685, required for dismantling of adherens junctions. Inhibition of NO formation by L-NMMA treatment suppresses vascular leakage also from established neovascular tufts, separating regulation of leakage from the angiogenic process as such. Mice expressing a VE-cadherin tyrosine to phenylalanine mutation (VEC-Y685F) are resistant to eNOS inhibition, supporting the model that NO regulates adherens junctions through direct effects on c-Src and VE-cadherin. These data suggest that eNOS/NO promote vascular permeability not only through the established effect on vSMC relaxation and increased flow-driven permeability to solute and small molecules in the precapillary arterial bed, but also through disruption of adherens junctions allowing leakage of larger molecules from the postcapillary venular bed.

The results presented here show that eNOS/NO plays a role in the postcapillary venous system by directly affecting the endothelial barrier to exacerbate vascular hyperpermeability in retinopathy (Figure 6). According to the consensus model, eNOS-generated NO regulates vascular permeability by inducing the relaxation of perivascular smooth muscle cells. NO produced in endothelial cells diffuses across the vascular wall and activates soluble guanylate cyclase leading to protein kinase G activation in vSMC, lowering cellular Ca²⁺, and promoting vascular relaxation, increased blood flow, and reduced blood pressure (Surks et al., 1999). Indeed, vessel dilation is a part of the tissue deterioration seen in diabetic retinopathy (Bek, 2013; Grimm and Willmann, 2012). However, there is also evidence for a direct role for eNOS and NO in endothelial cells, as constitutive eNOS deficiency inhibits inflammatory hyperpermeability in the mouse cremaster muscle treated with platelet-activating factor (Hatakeyama et al., 2006). Moreover, NO can regulate phosphorylation of VE-cadherin in adheren junctions in vitro in microvascular endothelial cell cultures (Di Lorenzo et al., 2013). It is likely that these multifaceted effects of eNOS/NO are differently established in different vessel types. eNOS/NO-dependent vessel dilation is dependent on the vSMC coverage in arterioles and arteries; in contrast, adherens junction stability affects mainly the postcapillary venular bed (Orsenigo et al., 2012). In the skin, prevenular capillaries and postcapillary venules, with sparse vSMC coverage, respond to VEGFA with increased paracellular permeability, while arterioles/arteries do not (Honkura et al., 2018). These distinctions are important as exaggerated and chronic VEGFA-driven paracellular permeability in disease leads to edema and eventually to tissue destruction (Nagy et al., 2012). Therefore, we explored the consequences of NO deficiency using a mutant eNOS mouse model, with a serine to alanine exchange at 1176, as well as treatment with the NO inhibitor L-NMMA, to examine how attenuating NO production affects VEGFA-dependent pathological angiogenesis in ocular disease.

Figure 6

Download asset Open asset

Our data shows that while the attenuation of eNOS S1176 phosphorylation was dispensable for vascular development in the retina and for endothelial survival during hyperoxia, growth of pathological vessel tufts in the subsequent phase of relative hypoxia was suppressed, while pericyte coverage and inflammation remained unaffected. Also, treatment with L-NMMA during the hypoxic phase reduced growth of vascular tufts in the retina. In agreement with earlier literature, we conclude that eNOS activity and NO formation influence pathological angiogenesis in the eye (Ando et al., 2002; Brooks et al., 2001; Edgar et al., 2012). Of note, tufts that were established in the Nos3^{S1176A/S1176A} mice leaked less, in spite of similar levels of VEGFA being produced as in the wild-type retina. In an attempt to mimic the clinical situation, we treated P16 mice with established vascular tufts with a single dose of L-NMMA. At the examination 24 hr later, tuft area remained unaffected, while the leakage of 25 nm microspheres was reduced by 50–60%. Whether leakage regulation is separable from the regulation of growth of new vessels has been a matter of debate. Pathological angiogenesis in the retina is intimately associated with leakage and edema (Smith et al., 2020). Exactly how junction stability plays a role in the neoangiogenic process is unclear. However, leakage and the production of a provisional matrix is postulated to be a prerequisite for the growth of angiogenic sprouts (reviewed in Nagy et al., 2012). With the effects of the L-NMMA intervention treatment shown here, we can conclude that these responses indeed can be separated, at least in the short term.

L-NMMA and its analog, L-NAME, induce vasoconstriction by halting the NO/soluble guanylyl cyclase signaling pathway and consequent vasodilation (reviewed in Ahmad et al., 2018; Thoonen et al., 2013). Thus, a daily intake of L-NAME in rats (40–75 μg/g/day for 4–8 weeks) leads to vasoconstriction (Ribeiro et al., 1992; Simko et al., 2018; Vrankova et al., 2019; Zanfolin et al., 2006). NOS inhibitors have also been used clinically, for example, by administration of L-NMMA to increase the mean arterial pressure in cardiogenic shock. In a typical regimen, 1 mg.kg⁻¹.hr⁻¹ of L-NMMA is administered over 5 hr (Cotter et al., 2000). While we cannot exclude an effect on vasoconstriction with the single IP injection of L-NMMA used here (60 μg/g), blood flow appeared unaffected as equal amounts of microspheres arrived in the retinal vasculature, while leakage into the extravascular space was substantially reduced in the L-NMMA treated mice compared to the controls. The leakage suppression did not involve changes in pericyte coverage of vessels or in the degree of inflammation. While perfusion was enhanced in tufts that still formed in the Nos3^{S1176A/S1176A} retinas after OIR-challenge, there was no effect on perfusion in tufts remaining after multiple- or single-dose L-NMMA treatment, possibly reflecting differences in tuft morphology and the degree of vessel patency.

Mechanistically, our results place c-Src downstream of eNOS activity. c-Src has also been placed upstream of eNOS by c-Src’s regulation of the PI3K-AKT pathway, of importance for eNOS activation (Haynes et al., 2003). VEGFR2-induced activation of c-Src has however been mapped to the pY949 residue in VEGFR2 (Li et al., 2016), while activation of Akt is dependent on Y1212 (Testini et al., 2019). In VEGFA-stimulated endothelial cells, c-Src is implicated in phosphorylation of VE-cadherin at Y685 and potentially other tyrosine residues, to induce vascular permeability (Orsenigo et al., 2012; Wallez et al., 2007). The fact that the mutant VEC-Y685F mice in which the Y685 residue has been replaced with a non-phosphorylatable phenylalanine were resistant to L-NMMA inhibition, indicates that the VEGFR2 Y1212/eNOS/NO pathway acts on adherens junction through c-Src (Li et al., 2016). Combined, our data support a model in which eNOS phosphorylation at S1176 is required for the activation of c-Src, which in turn phosphorylates VE-cadherin at Y685, inducing transient disintegration of adherens junctions and increased paracellular permeability (Figure 6). These in vivo results potentially provide meaningful mechanistic and therapeutic insights with regard to retinopathy of prematurity (Cunha-Vaz et al., 2011).

A considerable challenge in the analysis of c-Src activity is the close structural relatedness between the kinase domains of c-Src and the related SFKs Yes and Fyn (Sato et al., 2009), which are also expressed in endothelial cells. The amino acid sequence covering the activating tyrosine is entirely conserved between these three cytoplasmic tyrosine kinases such that the antibodies against pY418 c-Src in fact reacts with all three SFKs. In agreement, immunoblotting using antibodies against pY418 c-Src resulted in biphasic peaks of activity possibly reflecting activation of different SFKs. Moreover, pY418 immunostaining of wild-type and Nos3^{S1176A/S1176A} retinas after OIR failed to reveal a dependence on eNOS catalytic activity for activation of c-Src, in agreement with the findings of Di Lorenzo et al., 2013. However, combining oligonucleotide-linked secondary antibodies reacting with c-Src protein and pY418 Src in a PLA on isolated endothelial cells demonstrated a critical role for eNOS activity on accumulation of active, pY418-positive c-Src at endothelial junctions. The question remains how eNOS/NO influences c-Src activity? NO can couple with cysteine thiols to form S-nitroso-thiols, which may affect the folding and function of the target protein. In accordance, Rahman et al. demonstrated S-nitrosylation of c-Src at the kinase domain cysteine 498, correlating with increased c-Src activity (Rahman et al., 2010).

Although not experimentally addressed in this study, retinal diseases, such as diabetic retinopathy and adult macular degeneration, are accompanied by excessive permeability (Antonetti et al., 2012; Campochiaro, 2015). Of note, patients with diabetic retinopathy have elevated levels of NO in the aqueous humor, and particular eNOS polymorphisms are associated with protection or increased risk for diabetic retinopathy (for a review, see Opatrilova et al., 2018) and macular edema (Awata et al., 2004). Our results show that pharmacological inhibition of NO production after OIR challenge in mice can prevent vascular leakage. Thus, NO inhibitors applied in combination with anti-VEGF therapy, delivered in low but still efficient doses, could possibly be of clinical benefit. Local delivery of NOS inhibitors may be needed to avoid drawbacks with systemic delivery, such as hypertension, or any other vasoconstriction-associated adverse events. A limitation of the findings reported here was that neither the multiple-dose nor single-dose L-NMMA treatment improved perfusion of remaining tufts after OIR challenge. However, as tuft formation and leakage were suppressed with the multiple-dose treatment, a relative larger fraction of vessels remained healthy, with normal perfusion.

In conclusion, the data presented here establish a critical role for eNOS in endothelial cells, regulating c-Src activation downstream of VEGFA/VEGFR2, and thereby, in VE-cadherin-regulated endothelial junction stability and vascular leakage in retinal pathology.

All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 1–5. Source data files have also been deposited with Dryad: https://doi.org/10.5061/dryad.x69p8czhv.

1. 1. Love D
   2. Ninchoji T
   3. Claesson-Welsh L

   (2021) Dryad Digital Repository

   eNOS/NO and their role in modifying the vascular barrier in retinopathy - Source data.

   https://doi.org/10.5061/dryad.x69p8czhv

1. 1. Ahmad A
   2. Dempsey S
   3. Daneva Z
   4. Azam M
   5. Li N
   6. Li P-L
   7. Ritter J

   (2018) Role of nitric oxide in the cardiovascular and renal systems

   International Journal of Molecular Sciences 19:2605.

   https://doi.org/10.3390/ijms19092605

   • Google Scholar
2. 1. Ando A
   2. Yang A
   3. Mori K
   4. Yamada H
   5. Yamada E
   6. Takahashi K
   7. Saikia J
   8. Kim M
   9. Melia M
   10. Fishman M
   11. Huang P
   12. Campochiaro PA

   (2002) Nitric oxide is proangiogenic in the retina and choroid

   Journal of Cellular Physiology 191:116–124.

   https://doi.org/10.1002/jcp.10083

   • PubMed
   • Google Scholar
3. 1. Antonetti DA
   2. Klein R
   3. Gardner TW

   (2012) Diabetic retinopathy

   New England Journal of Medicine 366:1227–1239.

   https://doi.org/10.1056/NEJMra1005073

   • Google Scholar
4. 1. Awata T
   2. Neda T
   3. Iizuka H
   4. Kurihara S
   5. Ohkubo T
   6. Takata N
   7. Osaki M
   8. Watanabe M
   9. Nakashima Y
   10. Sawa T
   11. Inukai K
   12. Inoue I
   13. Shibuya M
   14. Mori K
   15. Yoneya S
   16. Katayama S

   (2004) Endothelial nitric oxide synthase gene is associated with diabetic macular edema in type 2 diabetes

   Diabetes Care 27:2184–2190.

   https://doi.org/10.2337/diacare.27.9.2184

   • PubMed
   • Google Scholar
5. 1. Bek T

   (2013) Regional morphology and pathophysiology of retinal vascular disease

   Progress in Retinal and Eye Research 36:247–259.

   https://doi.org/10.1016/j.preteyeres.2013.07.002

   • PubMed
   • Google Scholar
6. 1. Brooks SE
   2. Gu X
   3. Samuel S
   4. Marcus DM
   5. Bartoli M
   6. Huang PL
   7. Caldwell RB

   (2001)

   Reduced severity of oxygen-induced retinopathy in eNOS-deficient mice

   Investigative Ophthalmology & Visual Science 42:222–228.

   • PubMed
   • Google Scholar
7. 1. Campochiaro PA

   (2015) Molecular pathogenesis of retinal and choroidal vascular diseases

   Progress in Retinal and Eye Research 49:67–81.

   https://doi.org/10.1016/j.preteyeres.2015.06.002

   • PubMed
   • Google Scholar
8. 1. Canadian Neonatal Network and the Canadian Neonatal Follow-Up Network Investigators
   2. Morin J
   3. Luu TM
   4. Superstein R
   5. Ospina LH
   6. Lefebvre F
   7. Simard MN
   8. Shah V
   9. Shah PS
   10. Kelly EN

   (2016) Neurodevelopmental outcomes following Bevacizumab injections for retinopathy of prematurity

   Pediatrics 137:e20153218.

   https://doi.org/10.1542/peds.2015-3218

   • PubMed
   • Google Scholar
9. 1. Chen JX
   2. Meyrick B

   (2004) Hypoxia increases Hsp90 binding to eNOS via PI3K-Akt in porcine coronary artery endothelium

   Laboratory Investigation 84:182–190.

   https://doi.org/10.1038/labinvest.3700027

   • PubMed
   • Google Scholar
10. 1. Connor KM
    2. Krah NM
    3. Dennison RJ
    4. Aderman CM
    5. Chen J
    6. Guerin KI
    7. Sapieha P
    8. Stahl A
    9. Willett KL
    10. Smith LE

    (2009) Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis

    Nature Protocols 4:1565–1573.

    https://doi.org/10.1038/nprot.2009.187

    • PubMed
    • Google Scholar
11. 1. Cotter G
    2. Kaluski E
    3. Blatt A
    4. Milovanov O
    5. Moshkovitz Y
    6. Zaidenstein R
    7. Salah A
    8. Alon D
    9. Michovitz Y
    10. Metzger M
    11. Vered Z
    12. Golik A

    (2000) L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock

    Circulation 101:1358–1361.

    https://doi.org/10.1161/01.CIR.101.12.1358

    • PubMed
    • Google Scholar
12. 1. Cunha-Vaz J
    2. Bernardes R
    3. Lobo C

    (2011) Blood-Retinal barrier

    European Journal of Ophthalmology 21:3–9.

    https://doi.org/10.5301/EJO.2010.6049

    • Google Scholar
13. 1. Daruich A
    2. Matet A
    3. Moulin A
    4. Kowalczuk L
    5. Nicolas M
    6. Sellam A
    7. Rothschild PR
    8. Omri S
    9. Gélizé E
    10. Jonet L
    11. Delaunay K
    12. De Kozak Y
    13. Berdugo M
    14. Zhao M
    15. Crisanti P
    16. Behar-Cohen F

    (2018) Mechanisms of macular edema: beyond the surface

    Progress in Retinal and Eye Research 63:20–68.

    https://doi.org/10.1016/j.preteyeres.2017.10.006

    • PubMed
    • Google Scholar
14. 1. Di Lorenzo A
    2. Lin MI
    3. Murata T
    4. Landskroner-Eiger S
    5. Schleicher M
    6. Kothiya M
    7. Iwakiri Y
    8. Yu J
    9. Huang PL
    10. Sessa WC

    (2013) eNOS-derived nitric oxide regulates endothelial barrier function through VE-cadherin and rho GTPases

    Journal of Cell Science 126:5541–5552.

    https://doi.org/10.1242/jcs.115972

    • PubMed
    • Google Scholar
15. 1. Diabetic Retinopathy Clinical Research Network
    2. Wells JA
    3. Glassman AR
    4. Ayala AR
    5. Jampol LM
    6. Aiello LP
    7. Antoszyk AN
    8. Arnold-Bush B
    9. Baker CW
    10. Bressler NM
    11. Browning DJ
    12. Elman MJ
    13. Ferris FL
    14. Friedman SM
    15. Melia M
    16. Pieramici DJ
    17. Sun JK
    18. Beck RW

    (2015) Aflibercept, Bevacizumab, or ranibizumab for diabetic macular edema

    The New England Journal of Medicine 372:1193–1203.

    https://doi.org/10.1056/NEJMoa1414264

    • PubMed
    • Google Scholar
16. 1. Dor Y
    2. Porat R
    3. Keshet E

    (2001) Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis

    American Journal of Physiology-Cell Physiology 280:C1367–C1374.

    https://doi.org/10.1152/ajpcell.2001.280.6.C1367

    • PubMed
    • Google Scholar
17. 1. Edgar K
    2. Gardiner TA
    3. van Haperen R
    4. de Crom R
    5. McDonald DM

    (2012) eNOS overexpression exacerbates vascular closure in the obliterative phase of OIR and increases angiogenic drive in the subsequent proliferative stage

    Investigative Opthalmology & Visual Science 53:6833–6850.

    https://doi.org/10.1167/iovs.12-9797

    • Google Scholar
18. 1. Fruttiger M

    (2007) Development of the retinal vasculature

    Angiogenesis 10:77–88.

    https://doi.org/10.1007/s10456-007-9065-1

    • PubMed
    • Google Scholar
19. 1. Fukumura D
    2. Gohongi T
    3. Kadambi A
    4. Izumi Y
    5. Ang J
    6. Yun CO
    7. Buerk DG
    8. Huang PL
    9. Jain RK

    (2001) Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability

    PNAS 98:2604–2609.

    https://doi.org/10.1073/pnas.041359198

    • PubMed
    • Google Scholar
20. 1. Fulton D
    2. Gratton JP
    3. McCabe TJ
    4. Fontana J
    5. Fujio Y
    6. Walsh K
    7. Franke TF
    8. Papapetropoulos A
    9. Sessa WC

    (1999) Regulation of endothelium-derived nitric oxide production by the protein kinase akt

    Nature 399:597–601.

    https://doi.org/10.1038/21218

    • PubMed
    • Google Scholar
21. 1. Giannotta M
    2. Trani M
    3. Dejana E

    (2013) VE-Cadherin and endothelial adherens junctions: active guardians of vascular integrity

    Developmental Cell 26:441–454.

    https://doi.org/10.1016/j.devcel.2013.08.020

    • Google Scholar
22. 1. Grimm C
    2. Willmann G

    (2012) Hypoxia in the eye: a two-sided coin

    High Altitude Medicine & Biology 13:169–175.

    https://doi.org/10.1089/ham.2012.1031

    • PubMed
    • Google Scholar
23. 1. Hatakeyama T
    2. Pappas PJ
    3. Hobson RW
    4. Boric MP
    5. Sessa WC
    6. Durán WN

    (2006) Endothelial nitric oxide synthase regulates microvascular hyperpermeability in vivo

    The Journal of Physiology 574:275–281.

    https://doi.org/10.1113/jphysiol.2006.108175

    • PubMed
    • Google Scholar
24. 1. Haynes MP
    2. Li L
    3. Sinha D
    4. Russell KS
    5. Hisamoto K
    6. Baron R
    7. Collinge M
    8. Sessa WC
    9. Bender JR

    (2003) Src kinase mediates phosphatidylinositol 3-Kinase/Akt-dependent rapid endothelial Nitric-oxide synthase activation by estrogen

    Journal of Biological Chemistry 278:2118–2123.

    https://doi.org/10.1074/jbc.M210828200

    • Google Scholar
25. 1. Honkura N
    2. Richards M
    3. Laviña B
    4. Sáinz-Jaspeado M
    5. Betsholtz C
    6. Claesson-Welsh L

    (2018) Intravital imaging-based analysis tools for vessel identification and assessment of concurrent dynamic vascular events

    Nature Communications 9:2746.

    https://doi.org/10.1038/s41467-018-04929-8

    • PubMed
    • Google Scholar
26. 1. Kashiwagi S
    2. Atochin DN
    3. Li Q
    4. Schleicher M
    5. Pong T
    6. Sessa WC
    7. Huang PL

    (2013) eNOS phosphorylation on serine 1176 affects insulin sensitivity and adiposity

    Biochemical and Biophysical Research Communications 431:284–290.

    https://doi.org/10.1016/j.bbrc.2012.12.110

    • PubMed
    • Google Scholar
27. 1. Klaassen I
    2. Van Noorden CJ
    3. Schlingemann RO

    (2013) Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions

    Progress in Retinal and Eye Research 34:19–48.

    https://doi.org/10.1016/j.preteyeres.2013.02.001

    • PubMed
    • Google Scholar
28. 1. Krock BL
    2. Skuli N
    3. Simon MC

    (2011) Hypoxia-induced angiogenesis: good and evil

    Genes & Cancer 2:1117–1133.

    https://doi.org/10.1177/1947601911423654

    • PubMed
    • Google Scholar
29. 1. Li X
    2. Padhan N
    3. Sjöström EO
    4. Roche FP
    5. Testini C
    6. Honkura N
    7. Sáinz-Jaspeado M
    8. Gordon E
    9. Bentley K
    10. Philippides A
    11. Tolmachev V
    12. Dejana E
    13. Stan RV
    14. Vestweber D
    15. Ballmer-Hofer K
    16. Betsholtz C
    17. Pietras K
    18. Jansson L
    19. Claesson-Welsh L

    (2016) VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread

    Nature Communications 7:11017.

    https://doi.org/10.1038/ncomms11017

    • PubMed
    • Google Scholar
30. 1. Mintz-Hittner HA
    2. Kennedy KA
    3. Chuang AZ

    (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity

    New England Journal of Medicine 364:603–615.

    https://doi.org/10.1056/NEJMoa1007374

    • Google Scholar
31. 1. Nagy JA
    2. Dvorak AM
    3. Dvorak HF

    (2012) Vascular hyperpermeability, angiogenesis, and stroma generation

    Cold Spring Harbor Perspectives in Medicine 2:a006544.

    https://doi.org/10.1101/cshperspect.a006544

    • PubMed
    • Google Scholar
32. 1. Nishijima K
    2. Ng YS
    3. Zhong L
    4. Bradley J
    5. Schubert W
    6. Jo N
    7. Akita J
    8. Samuelsson SJ
    9. Robinson GS
    10. Adamis AP
    11. Shima DT

    (2007) Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury

    The American Journal of Pathology 171:53–67.

    https://doi.org/10.2353/ajpath.2007.061237

    • PubMed
    • Google Scholar
33. 1. Opatrilova R
    2. Kubatka P
    3. Caprnda M
    4. Büsselberg D
    5. Krasnik V
    6. Vesely P
    7. Saxena S
    8. Ruia S
    9. Mozos I
    10. Rodrigo L
    11. Kruzliak P
    12. Dos Santos KG

    (2018) Nitric oxide in the pathophysiology of retinopathy: evidences from preclinical and clinical researches

    Acta Ophthalmologica 96:222–231.

    https://doi.org/10.1111/aos.13384

    • PubMed
    • Google Scholar
34. 1. Orsenigo F
    2. Giampietro C
    3. Ferrari A
    4. Corada M
    5. Galaup A
    6. Sigismund S
    7. Ristagno G
    8. Maddaluno L
    9. Koh GY
    10. Franco D
    11. Kurtcuoglu V
    12. Poulikakos D
    13. Baluk P
    14. McDonald D
    15. Grazia Lampugnani M
    16. Dejana E

    (2012) Phosphorylation of VE-cadherin is modulated by haemodynamic forces and contributes to the regulation of vascular permeability in vivo

    Nature Communications 3:1208.

    https://doi.org/10.1038/ncomms2199

    • PubMed
    • Google Scholar
35. 1. Patel A
    2. Cholkar K
    3. Agrahari V
    4. Mitra AK

    (2013) Ocular drug delivery systems: an overview

    World Journal of Pharmacology 2:47–64.

    https://doi.org/10.5497/wjp.v2.i2.47

    • PubMed
    • Google Scholar
36. 1. Prahst C
    2. Ashrafzadeh P
    3. Mead T
    4. Figueiredo A
    5. Chang K
    6. Richardson D
    7. Venkaraman L
    8. Richards M
    9. Russo AM
    10. Harrington K
    11. Ouarné M
    12. Pena A
    13. Chen DF
    14. Claesson-Welsh L
    15. Cho KS
    16. Franco CA
    17. Bentley K

    (2020) Mouse retinal cell behaviour in space and time using light sheet fluorescence microscopy

    eLife 9:e49779.

    https://doi.org/10.7554/eLife.49779

    • PubMed
    • Google Scholar
37. 1. Rahman MA
    2. Senga T
    3. Ito S
    4. Hyodo T
    5. Hasegawa H
    6. Hamaguchi M

    (2010) S-Nitrosylation at cysteine 498 of c-Src tyrosine kinase regulates nitric Oxide-mediated cell invasion

    Journal of Biological Chemistry 285:3806–3814.

    https://doi.org/10.1074/jbc.M109.059782

    • Google Scholar
38. 1. Ribeiro MO
    2. Antunes E
    3. de Nucci G
    4. Lovisolo SM
    5. Zatz R

    (1992) Chronic inhibition of nitric oxide synthesis A new model of arterial hypertension

    Hypertension 20:298–303.

    https://doi.org/10.1161/01.HYP.20.3.298

    • PubMed
    • Google Scholar
39. 1. Sato I
    2. Obata Y
    3. Kasahara K
    4. Nakayama Y
    5. Fukumoto Y
    6. Yamasaki T
    7. Yokoyama KK
    8. Saito T
    9. Yamaguchi N

    (2009) Differential trafficking of src, lyn, yes and fyn is specified by the state of palmitoylation in the SH4 domain

    Journal of Cell Science 122:965–975.

    https://doi.org/10.1242/jcs.034843

    • PubMed
    • Google Scholar
40. 1. Schleicher M
    2. Yu J
    3. Murata T
    4. Derakhshan B
    5. Atochin D
    6. Qian L
    7. Kashiwagi S
    8. Di Lorenzo A
    9. Harrison KD
    10. Huang PL
    11. Sessa WC

    (2009) The Akt1-eNOS Axis illustrates the specificity of kinase-substrate relationships in vivo

    Science Signaling 2:ra41.

    https://doi.org/10.1126/scisignal.2000343

    • PubMed
    • Google Scholar
41. 1. Scott A
    2. Fruttiger M

    (2010) Oxygen-induced retinopathy: a model for vascular pathology in the retina

    Eye 24:416–421.

    https://doi.org/10.1038/eye.2009.306

    • PubMed
    • Google Scholar
42. 1. Semenza GL

    (2012) Hypoxia-inducible factors in physiology and medicine

    Cell 148:399–408.

    https://doi.org/10.1016/j.cell.2012.01.021

    • PubMed
    • Google Scholar
43. 1. Sessa WC

    (2004) eNOS at a glance

    Journal of Cell Science 117:2427–2429.

    https://doi.org/10.1242/jcs.01165

    • PubMed
    • Google Scholar
44. 1. Simko F
    2. Baka T
    3. Krajcirovicova K
    4. Repova K
    5. Aziriova S
    6. Zorad S
    7. Poglitsch M
    8. Adamcova M
    9. Reiter R
    10. Paulis L

    (2018) Effect of melatonin on the Renin-Angiotensin-Aldosterone system in l-NAME-Induced hypertension

    Molecules 23:265.

    https://doi.org/10.3390/molecules23020265

    • Google Scholar
45. 1. Smith LE
    2. Wesolowski E
    3. McLellan A
    4. Kostyk SK
    5. D'Amato R
    6. Sullivan R
    7. D'Amore PA

    (1994)

    Oxygen-induced retinopathy in the mouse

    Investigative Ophthalmology & Visual Science 35:101–111.

    • PubMed
    • Google Scholar
46. 1. Smith RO
    2. Ninchoji T
    3. Gordon E
    4. André H
    5. Dejana E
    6. Vestweber D
    7. Kvanta A
    8. Claesson-Welsh L

    (2020) Vascular permeability in retinopathy is regulated by VEGFR2 Y949 signaling to VE-cadherin

    eLife 9:e54056.

    https://doi.org/10.7554/eLife.54056

    • PubMed
    • Google Scholar
47. 1. Söderberg O
    2. Gullberg M
    3. Jarvius M
    4. Ridderstråle K
    5. Leuchowius KJ
    6. Jarvius J
    7. Wester K
    8. Hydbring P
    9. Bahram F
    10. Larsson LG
    11. Landegren U

    (2006) Direct observation of individual endogenous protein complexes in situ by proximity ligation

    Nature Methods 3:995–1000.

    https://doi.org/10.1038/nmeth947

    • PubMed
    • Google Scholar
48. 1. Surks HK
    2. Mochizuki N
    3. Kasai Y
    4. Georgescu SP
    5. Tang KM
    6. Ito M
    7. Lincoln TM
    8. Mendelsohn ME

    (1999) Regulation of myosin phosphatase by a specific interaction with cGMP- dependent protein kinase ialpha

    Science 286:1583–1587.

    https://doi.org/10.1126/science.286.5444.1583

    • PubMed
    • Google Scholar
49. 1. Testini C
    2. Smith RO
    3. Jin Y
    4. Martinsson P
    5. Sun Y
    6. Hedlund M
    7. Sáinz-Jaspeado M
    8. Shibuya M
    9. Hellström M
    10. Claesson-Welsh L

    (2019) Myc-dependent endothelial proliferation is controlled by phosphotyrosine 1212 in VEGF receptor-2

    EMBO Reports 20:e47845.

    https://doi.org/10.15252/embr.201947845

    • PubMed
    • Google Scholar
50. 1. Thoonen R
    2. Sips PY
    3. Bloch KD
    4. Buys ES

    (2013) Pathophysiology of hypertension in the absence of nitric oxide/cyclic GMP signaling

    Current Hypertension Reports 15:47–58.

    https://doi.org/10.1007/s11906-012-0320-5

    • PubMed
    • Google Scholar
51. 1. Thors B
    2. Halldórsson H
    3. Thorgeirsson G

    (2004) Thrombin and histamine stimulate endothelial nitric-oxide synthase phosphorylation at Ser1177 via an AMPK mediated pathway independent of PI3K-Akt

    FEBS Letters 573:175–180.

    https://doi.org/10.1016/j.febslet.2004.07.078

    • PubMed
    • Google Scholar
52. 1. Vrankova S
    2. Zemancikova A
    3. Torok J
    4. Pechanova O

    (2019) Effect of low dose L-NAME pretreatment on nitric oxide/reactive oxygen species balance and vasoactivity in L-NAME/salt-induced hypertensive rats

    Journal of Physiology and Pharmacology  70:5.

    https://doi.org/10.26402/jpp.2019.4.05

    • Google Scholar
53. 1. Wallez Y
    2. Cand F
    3. Cruzalegui F
    4. Wernstedt C
    5. Souchelnytskyi S
    6. Vilgrain I
    7. Huber P

    (2007) Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site

    Oncogene 26:1067–1077.

    https://doi.org/10.1038/sj.onc.1209855

    • PubMed
    • Google Scholar
54. 1. Wessel F
    2. Winderlich M
    3. Holm M
    4. Frye M
    5. Rivera-Galdos R
    6. Vockel M
    7. Linnepe R
    8. Ipe U
    9. Stadtmann A
    10. Zarbock A
    11. Nottebaum AF
    12. Vestweber D

    (2014) Leukocyte extravasation and vascular permeability are each controlled in vivo by different tyrosine residues of VE-cadherin

    Nature Immunology 15:223–230.

    https://doi.org/10.1038/ni.2824

    • PubMed
    • Google Scholar
55. 1. Zanfolin M
    2. Faro R
    3. Araujo EG
    4. Guaraldo AM
    5. Antunes E
    6. De Nucci G

    (2006) Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats

    Journal of Cardiovascular Pharmacology 47:391–395.

    https://doi.org/10.1097/00004872-200402001-00254

    • PubMed
    • Google Scholar
56. 1. Zhao Z
    2. Nelson AR
    3. Betsholtz C
    4. Zlokovic BV

    (2015) Establishment and dysfunction of the Blood-Brain barrier

    Cell 163:1064–1078.

    https://doi.org/10.1016/j.cell.2015.10.067

    • PubMed
    • Google Scholar

Acceptance summary:

The strength of this study is to clarify the roles of eNOS in ischemic neovascularization and vessel permeability using an oxygen-induced retinopathy (OIR) mouse model. It shows that either systemic NO formation inhibitor L-NMMA or eNOS (S1176A) mutant causes reduced retinal vascular tuft formation, and also reduces vascular leakage by stabilizing VE-cadherin in a c-Src-dependent manner. It also shows that a single dose of L-NMMA restores the vascular barrier and prevents leakage. Based on these findings, they have concluded that eNOS induces destabilization of adherens junctions and vascular hyperpermeability by converging with the VEGFA/VEGFR2/c43 Src/VE-cadherin pathway and that this pathway can be selectively inhibited by blocking NO formation. This study is well-designed and well-presented, and mechanistically solid.

Decision letter after peer review:

Thank you for submitting your article "eNOS-induced vascular barrier disruption in retinopathy by c-Src activation and tyrosine phosphorylation of VE-cadherin" for consideration by eLife. Your article has been reviewed by 2 peer reviewers, including Gou Young Koh as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Didier Stainier as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our policy on revisions we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, when editors judge that a submitted work as a whole belongs in eLife but that some conclusions require a modest amount of additional new data, as they do with your paper, we are asking that the manuscript be revised to either limit claims to those supported by data in hand, or to explicitly state that the relevant conclusions require additional supporting data.

Our expectation is that the authors will eventually carry out the additional experiments and report on how they affect the relevant conclusions either in a preprint on bioRxiv or medRxiv, or if appropriate, as a Research Advance in eLife, either of which would be linked to the original paper.

The comments of all two reviewers are in good agreement. While the reviewers found this study is well-designed and well-presented, mechanistically solid, and to be of importance as a translational research, they raised concerns about the limitation to be generalized to apply major ocular diseases including wet-AMD and diabetic retinopathy and the inconsistencies of the results and interpretations to the previous reports. The authors are required to carefully address the comments point-by-point in a data-driven manner or with further analyses or discussions. Specifically, the authors are encouraged to pay attention to the major comments 2 and 3 of reviewer 1 and comments 1 and 2 of reviewer 2. If necessary, please provide the reasons for not implementing the suggested changes.

Reviewer #1:

This study has elegantly clarified the role of eNOS in ischemic neovascularization and vessel permeability using an oxygen-induced retinopathy (OIR) mouse model. The authors show that either systemic NO formation inhibitor L-NMMA or eNOS (S1176A) mutant causes reduced retinal vascular tuft formation, and also reduces vascular leakage by stabilizing VE-cadherin in a c-Src-dependent manner. Because the OIR model can reflect only "retinopathy of prematurity" in premature newborns but cannot fully reflect wet-AMD (in fact, choroidal vessel disease) and diabetic retinopathy in adult, this study has a limitation to be generalized to apply major ocular diseases including wet-AMD and diabetic retinopathy. Nevertheless, this study is well-designed and well-presented, and mechanistically solid, and thus it deserves to be published in eLife.

The study conducted by Ninchoji et al. has clarified the role of eNOS in ischemic neovascularization and vessel permeability using an oxygen-induced retinopathy (OIR) mouse model. They show that either systemic NO formation inhibitor L-NMMA or eNOS (S1176A) mutant causes reduced retinal vascular tuft formation, and also reduces vascular leakage by stabilizing VE-cadherin in a c-Src-dependent manner. They also show that a single dose of L-NMMA restores the vascular barrier and prevents leakage. Based on these findings, they have concluded that eNOS induces destabilization of adherens junctions and vascular hyperpermeability by converging with the VEGFA/VEGFR2/c43 Src/VE-cadherin pathway and that this pathway can be selectively inhibited by blocking NO formation. This study is well-designed and well-presented, and mechanistically solid. However, the following comments need to be appropriately addressed:

1. The OIR model can reflect "retinopathy of prematurity" in premature newborns but cannot fully reflect wet-AMD (in fact, choroidal vessel disease) and diabetic retinopathy in adult. Therefore, the authors need to tone down the generalization and limit the applicability.

2. Pericyte dropout and infiltration of macrophages are critical components to vascular leakage in the OIR model, as shown in recent papers (Park et al., Nature Communication, 2017; Ogura et al., JCI Insight 2017; Omori et al., JCI Insight 2018). What are the changes in PC-EC coupling and macrophage infiltration in either L-NMMA treatment or eNOS(S1176A) mutant by OIR.

3. Because the vascular tuft and deformed vessels formed by OIR have generally no circulation, it causes severe hypoxia or anoxia to the retinal neurons. Is there restoration in the retinal circulation after L-NMMA treatment? It can be measured by a lectin perfusion assay.

4. Restoration of functional blood vessels in the avascular area is the most important point for treating the patients of "retinopathy of prematurity". In this regard, single treatment of NMMA is not sufficient. Therefore, the description of this therapeutic option needs to be further defined.

Reviewer #3:

Ninchoji T. et al. demonstrated the signaling cascade that worsens the endothelial cell (EC) barrier function by phosphorylating vascular endothelial cadherin (VE-cadherin). The effect of endothelial NO synthetase (eNOS, Nos3) on barrier function has been different in different vessel types and in different disease models. In addition, it is also controversial whether c-Src is upstream or downstream of eNOS. The authors delineate the signaling cascade that regulates retinal barrier function using the mice (genetically mutated Nos3 (S1176A) that cannot be phosphorylated) and the mice (VEC-Y685F) in which VE-cadherin cannot be phosphorylated in oxygen-induced retinopathy (OIR) model.

The authors extended their previous results reported in eLife (Smith et al. eLife 2020;9: e54056) to show the VEGF-dependent vascular leakage in OIR model. Previously, they reported that phosphorylation of VE-cadherin Y685 results in vessel leakage. In the present study, they analyzed Tuft area and avascular area similarly to the previous report and delineated the VEGF/VEGFR2-dependent signaling that causes vascular leakage. In the mice in which Nos3S1176A was knocked-in, vascular leakage was suppressed. Moreover, VEC-Y685F mutant mice showed less tuft area than wildtype. This is consistent with their previous result. The reduction in tuft area was comparable in PBS and L-NMMA-treated Y685F mouse retinas and that seen in L-NMMA-treated wildtype mice. The involvement of C-Src downstream of VEGF/VEGFR2-eNOS was shown in proximity ligation assay (PLA). Collectively, they delineate the signaling mediated by VEGF/VEGFR2-eNOS (S1176 phosphorylation)-c-Src (Y418 phosphorylation)-VE-cad(Y685 phosphorylation) that induces leakage in OIR model.

The signaling cascade is proven by the two different knock-iin mice (Nos3 S1176A and VEC Y685F) in the established OIR model in vivo, while other groups show eNOS-dependent barrier stabilization effect on ECs in different model.

1. Involvement of c-Src in OIR

There is one inconsistency in the model illustrated in Figure 6. In the previous report by Smith (the same group), the authors mentioned that pY949 is VEGFR2 appeared not to contribute to regulation of c-Src kinase activity in the retina vasculature. However, the model in Figure 6 clearly points to the Y949 of VEGFR2 and c-Src Y418. Considering the previous results and the new results, the authors need to revise the involvement of c-Src in OIR model Immunoblot analyses of in vitro assay using human retinal microvascular endothelial cells might help the readers to understand the upstream and downstream of VEGFR2; namely AKT-eNOS-c-Src and another direct c-Src-mediated VE-cad phosphorylation by showing time course of phosphorylation of Akt and eNOS. In addition to this, c-Src phosphorylation might be analyzed in a time-dependent manner, although Fyn or Yes might be similarly phosphorylated. At least, time course can be analyzed.

2. Anti-VEGF therapy

The authors describe the disadvantage of anti-VEGF therapy in the introduction. However, the vascular leakage in OIR is dependent on VEGF/VEGFR2 as illustrated in Figure 6. Why is anti-VEGF therapy ineffective in OIR? VEGF-dependent eNOS activation should be inhibited by ant-VEGF therapy. Because L-NMMA might become a potential candidate as an ant-eNOS therapy, the authors had better mention the usefulness of this as an alternative or additional therapy for retinopathy.

3. The intensity of red in Figure 2 -supplement figure 2c is too low. These panels should be replaced.

4. L-NMMA should be explained when it appears first in page 9 instead of page 11

Reviewer #1:

This study has elegantly clarified the role of eNOS in ischemic neovascularization and vessel permeability using an oxygen-induced retinopathy (OIR) mouse model. The authors show that either systemic NO formation inhibitor L-NMMA or eNOS (S1176A) mutant causes reduced retinal vascular tuft formation, and also reduces vascular leakage by stabilizing VE-cadherin in a c-Src-dependent manner. Because the OIR model can reflect only "retinopathy of prematurity" in premature newborns but cannot fully reflect wet-AMD (in fact, choroidal vessel disease) and diabetic retinopathy in adult, this study has a limitation to be generalized to apply major ocular diseases including wet-AMD and diabetic retinopathy. Nevertheless, this study is well-designed and well-presented, and mechanistically solid, and thus it deserves to be published in eLife.

The study conducted by Ninchoji et al. has clarified the role of eNOS in ischemic neovascularization and vessel permeability using an oxygen-induced retinopathy (OIR) mouse model. They show that either systemic NO formation inhibitor L-NMMA or eNOS (S1176A) mutant causes reduced retinal vascular tuft formation, and also reduces vascular leakage by stabilizing VE-cadherin in a c-Src-dependent manner. They also show that a single dose of L-NMMA restores the vascular barrier and prevents leakage. Based on these findings, they have concluded that eNOS induces destabilization of adherens junctions and vascular hyperpermeability by converging with the VEGFA/VEGFR2/c43 Src/VE-cadherin pathway and that this pathway can be selectively inhibited by blocking NO formation. This study is well-designed and well-presented, and mechanistically solid. However, the following comments need to be appropriately addressed:

1. The OIR model can reflect "retinopathy of prematurity" in premature newborns but cannot fully reflect wet-AMD (in fact, choroidal vessel disease) and diabetic retinopathy in adult. Therefore, the authors need to tone down the generalization and limit the applicability.

We thank the reviewer for the appreciative comments. We concur with the reviewer’s description of the limitation of the OIR model and have toned down the generalization and applicability. See track changes in the discussion, lines 664-666, 675-679.

2. Pericyte dropout and infiltration of macrophages are critical components to vascular leakage in the OIR model, as shown in recent papers (Park et al., Nature Communication, 2017; Ogura et al., JCI Insight 2017; Omori et al., JCI Insight 2018). What are the changes in PC-EC coupling and macrophage infiltration in either L-NMMA treatment or eNOS(S1176A) mutant by OIR.

We have now performed new experiments and measured NG2-positive pericyte coating and the presence of CD68-positive macrophages in retinas after OIRchallenge of wildtype or Nos3^{S1176A/Nos3S1176A} mutant mice, as well as mice treated with multiple or single dose of L-NMMA. The extent of pericyte coating and macrophage infiltration was the same in all conditions. These data are now shown in Figure 1—figure supplement 3, Figure 4—figure supplement 1 and Figure 5—figure supplement 1.

3. Because the vascular tuft and deformed vessels formed by OIR have generally no circulation, it causes severe hypoxia or anoxia to the retinal neurons. Is there restoration in the retinal circulation after L-NMMA treatment? It can be measured by a lectin perfusion assay.

We have now performed perfusion using fluorescent lectin and although perfusion is increased in tufts formed in the Nos3^{S1176A/Nos3S1176A} mutant mice, there was no change in perfusion of tufts formed after multiple or single-dose treatment with L-NMMA (see Figure 4—figure supplement 1 and Figure 5—figure supplement 1). We have added a comment on the lack of improved perfusion in the discussion, lines 625-628.

4. Restoration of functional blood vessels in the avascular area is the most important point for treating the patients of "retinopathy of prematurity". In this regard, single treatment of NMMA is not sufficient. Therefore, the description of this therapeutic option needs to be further defined.

We thank the reviewer for this comment and we of course agree. The single-dose treatment was a useful strategy in distinguishing the effects of the LNMMA treatment on tuft formation (which was unchanged with the single dose) and leakage (which was suppressed). The clinical implication of the L-NMMA treatment we agree was overemphasized and has now been toned down throughout.

Reviewer #3:

Ninchoji T. et al. demonstrated the signaling cascade that worsens the endothelial cell (EC) barrier function by phosphorylating vascular endothelial cadherin (VE-cadherin). The effect of endothelial NO synthetase (eNOS, Nos3) on barrier function has been different in different vessel types and in different disease models. In addition, it is also controversial whether c-Src is upstream or downstream of eNOS. The authors delineate the signaling cascade that regulates retinal barrier function using the mice (genetically mutated Nos3 (S1176A) that cannot be phosphorylated) and the mice (VEC-Y685F) in which VE-cadherin cannot be phosphorylated in oxygen-induced retinopathy (OIR) model.

The authors extended their previous results reported in eLife (Smith et al. eLife 2020;9: e54056) to show the VEGF-dependent vascular leakage in OIR model. Previously, they reported that phosphorylation of VE-cadherin Y685 results in vessel leakage. In the present study, they analyzed Tuft area and avascular area similarly to the previous report and delineated the VEGF/VEGFR2-dependent signaling that causes vascular leakage. In the mice in which Nos3S1176A was knocked-in, vascular leakage was suppressed. Moreover, VEC-Y685F mutant mice showed less tuft area than wildtype. This is consistent with their previous result. The reduction in tuft area was comparable in PBS and L-NMMA-treated Y685F mouse retinas and that seen in L-NMMA-treated wildtype mice. The involvement of C-Src downstream of VEGF/VEGFR2-eNOS was shown in proximity ligation assay (PLA). Collectively, they delineate the signaling mediated by VEGF/VEGFR2-eNOS (S1176 phosphorylation)-c-Src (Y418 phosphorylation)-VE-cad(Y685 phosphorylation) that induces leakage in OIR model.

The signaling cascade is proven by the two different knock-iin mice (Nos3 S1176A and VEC Y685F) in the established OIR model in vivo, while other groups show eNOS-dependent barrier stabilization effect on ECs in different model.

1. Involvement of c-Src in OIR

There is one inconsistency in the model illustrated in Figure 6. In the previous report by Smith (the same group), the authors mentioned that pY949 is VEGFR2 appeared not to contribute to regulation of c-Src kinase activity in the retina vasculature. However, the model in Figure 6 clearly points to the Y949 of VEGFR2 and c-Src Y418. Considering the previous results and the new results, the authors need to revise the involvement of c-Src in OIR model Immunoblot analyses of in vitro assay using human retinal microvascular endothelial cells might help the readers to understand the upstream and downstream of VEGFR2; namely AKT-eNOS-c-Src and another direct c-Src-mediated VE-cad phosphorylation by showing time course of phosphorylation of Akt and eNOS. In addition to this, c-Src phosphorylation might be analyzed in a time-dependent manner, although Fyn or Yes might be similarly phosphorylated. At least, time course can be analyzed.

We have followed the reviewer’s suggestion and now provide a time course where the effects of L-NMMA treatment on VEGFA-induced phosphorylation of eNOS, AKT, VE-cadherin and Src have been examined (see Figure 2 – suppl figure 1, lines 452-464). Interestingly, VEGFA induces a biphasic pY418 signal and one of them, the second peak, is inhibited by L-NMMA. We suggest that the different peaks may represent activation of different Src family kinases as the pY418 antibody does not distinguish between c-Src, Yes and Fyn. We therefore would like to keep the PLA results, which allows a firm conclusion on the effect of L-NMMA specifically on c-Src activation. Of note, a PLA signal will be generated when the secondary antibodies detect the primary antibodies (against c-Src protein and against pY418) in close proximity, i.e. when c-Src is phosphorylated on Y418. We have gone through the text and figures to ensure we have described this clearly, for example in Figure 4C, which was erroneously labeled before. We apologize for this oversight.

Taken together, we are not yet ready to revise the involvement of c-Src in the OIR model as the PLA results show activation of c-Src in an eNOS dependent manner at endothelial junctions. To bring this further, we need even more refined tools. Indeed, detailed analyses of the specific biological roles of Src, Yes and Fyn in endothelial cell-specific deletion mouse models have been initiated in our group, but these are challenging projects in their own rights.

2. Anti-VEGF therapy

The authors describe the disadvantage of anti-VEGF therapy in the introduction. However, the vascular leakage in OIR is dependent on VEGF/VEGFR2 as illustrated in Figure 6. Why is anti-VEGF therapy ineffective in OIR? VEGF-dependent eNOS activation should be inhibited by ant-VEGF therapy. Because L-NMMA might become a potential candidate as an ant-eNOS therapy, the authors had better mention the usefulness of this as an alternative or additional therapy for retinopathy.

The standard clinical treatment by now is anti-VEGF therapy and we describe the limitation of this therapy in the introduction. The problem is not necessarily that it is ineffective but rather that it has side effects by targeting VEGFR2 on endothelial cells as well as on neurons. See Introduction, lines 77-83. As suggested by Reviewer 1, we have now toned down the clinical perspective which we agree was overemphasized. However, please see the discussion, lines 672-673, where the potential usefulness of combinatorial treatment with anti-VEGF and NO suppressive drugs was already mentioned.

3. The intensity of red in Figure 2 -supplement figure 2c is too low. These panels should be replaced.

Figure 2 -suppl figure 2c show the PLA controls and these were negative – no signal. The images are representative and have been kept.

4. L-NMMA should be explained when it appears first in page 9 instead of page 11

Amended.

Author details

1. Takeshi Ninchoji

   Uppsala University, Rudbeck Laboratory, Department of Immunology, Genetics and Pathology, Uppsala, Sweden

   Contribution

   Conceptualization, Formal analysis, Validation, Investigation, Visualization, Writing - review and editing

   Contributed equally with

   Dominic T Love

   For correspondence

   nincho830@gmail.com

   Competing interests

   No competing interests declared

2. Dominic T Love

   Uppsala University, Rudbeck Laboratory, Department of Immunology, Genetics and Pathology, Uppsala, Sweden

   Contribution

   Conceptualization, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - review and editing

   Contributed equally with

   Takeshi Ninchoji

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0001-8530-1352

3. Ross O Smith

   Uppsala University, Rudbeck Laboratory, Department of Immunology, Genetics and Pathology, Uppsala, Sweden

   Contribution

   Supervision, Methodology, Writing - review and editing

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0003-4239-3204

4. Marie Hedlund

   Uppsala University, Rudbeck Laboratory, Department of Immunology, Genetics and Pathology, Uppsala, Sweden

   Contribution

   Investigation, Writing - review and editing

   Competing interests

   No competing interests declared

5. Dietmar Vestweber

   Max Planck Institute for Molecular Biomedicine, Münster, Germany

   Contribution

   Resources, Writing - review and editing

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-3517-732X

6. William C Sessa

   Yale University School of Medicine, Department of Pharmacology and Vascular Biology and Therapeutics Program, New Haven, United States

   Contribution

   Resources, Writing - review and editing

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0001-5759-1938

7. Lena Claesson-Welsh

   Uppsala University, Rudbeck Laboratory, Department of Immunology, Genetics and Pathology, Uppsala, Sweden

   Contribution

   Conceptualization, Resources, Supervision, Funding acquisition, Writing - original draft, Project administration, Writing - review and editing

   For correspondence

   lena.welsh@igp.uu.se

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0003-4275-2000

• 1,751

  Page views

• 235

  Downloads

• 14

  Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.